Research includes innovations in mRNA and protein engineering and delivery science to improve therapeutic properties

Highlights research results from ongoing collaborations with International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID) and Bill & Melinda Gates Foundation toward development of an HIV vaccine

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new research to be highlighted at the Company’s third annual Science Day, held virtually this year. The program is designed to provide insight into the continued diverse efforts underway at Moderna and with collaborators to better understand how to use mRNA as a medicine, and underscores the Company’s continued commitment to basic science and innovation.

“Science Day is an opportunity for us to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as a medicine. Our substantial investments in basic science to date have resulted in major steps forward in our platform’s capabilities, and these have allowed us to open new therapeutic areas and new scientific directions,” said Stephen Hoge, M.D., President of Moderna. “Today, we’re excited to highlight novel approaches to our lipid nanoparticle technology, which will be used with mRNA-3745, our GSD1a candidate in preclinical development. We are also pleased to provide an update on our collaboration with IAVI, NIAID and Bill & Melinda Gates Foundation toward the development of an HIV vaccine using Moderna’s mRNA platform. We remain firmly committed to further advancing our mRNA science to create a new generation of transformative medicines for patients.”

At this year’s Science Day, Moderna will present new platform science and preclinical research, including:

Engineering mRNA and Proteins to Improve Therapeutic Properties

An advantage of mRNA medicines over small molecule drugs is the ease of engineering their properties to achieve desired pharmacology. New research will be presented on efforts to engineer both mRNAs and encoded proteins to improve and extend therapeutic effect.

These efforts include modifications to mRNA and proteins to prevent degradation and lengthen half-life. Presentations will include data on the addition of an inverted deoxythymidine (idT) to the 3’-end of mRNA, which is designed to stabilize mRNA by blocking its degradation through deadenylation. Preclinical data show that 3’-idT-stabilized mRNA encoding phenylalanine hydroxylase (PAH), the enzyme missing or dysfunctional in the metabolic disorder phenylketonuria (PKU), supports sustained reduction of serum phenylalanine levels in a PKU mouse model. Data will also be presented on removal of ubiquitination sites from PAH, designed to prevent ubiquitin-mediated protein degradation. Results show that combining mRNA stabilization along with PAH stabilization maintained low serum phenylalanine levels even further, suggesting an additive effect.

One challenge for the production of mRNA therapeutics is to minimize or eliminate double-stranded RNA (dsRNA) impurities produced during the synthesis process, as this can trigger undesirable innate immune responses in vivo. At Science Day, Moderna will present a protein engineering workflow by which it has engineered a Moderna T7 RNA polymerase (MT7) that does not produce dsRNA impurities.

Optimizing Lipid Nanoparticle Technology

The Company will present new research in delivery science to optimize its lipid nanoparticles (LNPs). The presentations will highlight a novel squaramide-based ionizable lipid designed to enhance the interactions between the lipid and mRNA. Preclinical data from new LNPs incorporating this novel ionizable lipid show improved protein expression after IV administration, including repeat dosing, and efficient delivery to the liver, as compared to current state-of-the-art Moderna proprietary LNPs.

This squaramide-based LNP represents a new delivery system and will be used with the Company’s glycogen storage disease type 1a (GSD1a) candidate (mRNA-3745), which is in preclinical development. Preclinical studies with this new LNP containing mRNA encoding for G6Pase, the missing or dysfunctional enzyme in GSD1a, show sustained improvements in fasting blood glucose in a mouse model of GSD1a, achieving the target product profile.

Collaborating on an HIV Vaccine

Science Day will also include presentations from William Schief, Ph.D., Professor, Immunology and Microbiology, Scripps Research Institute and Executive Director, Vaccine Design, International Aids Vaccine Initiative (IAVI) and Paolo Lusso, M.D., Ph.D., Chief, Viral Pathogenesis, Laboratory of Immmunoregulation, National Institute of Allergy and Infectious Diseases (NIAID)​ showcasing research conducted through Moderna’s ongoing collaborations with IAVI, NIAID and the Bill & Melinda Gates Foundation. This research seeks to deliver an engineered HIV immunogen using Moderna’s mRNA platform that allows for a faster, more flexible approach to rapid iterative vaccine design and clinical testing. This approach could significantly accelerate early clinical trials and transform HIV vaccine science and development efforts. The data presented today will highlight progress toward creating a protective HIV-1 vaccine designed to elicit broadly neutralizing antibodies to prevent HIV-1 infection.

Moderna currently has 23 mRNA development candidates in its portfolio with 13 in clinical studies. Across Moderna’s pipeline, more than 1,900 participants have been enrolled in clinical studies. The Company’s updated pipeline can be found at www.modernatx.com/pipeline. Moderna and collaborators have published more than 45 peer-reviewed papers.

Science Day Webcast Information

Moderna will host its annual Science Day for analysts and investors at 8:00 a.m. ET on Tuesday, June 2. A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for one year following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s mRNA and encoded protein engineering efforts, the Company’s new squaramide-based LNP and its expected use with mRNA-3745 and other new development candidates, the potential for the Company’s mRNA platform to significantly accelerate early clinical trials and transform HIV vaccine science and development efforts, and the presentation of research and data at the Company’s upcoming Science Day. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. 

Contacts

Moderna Contacts

Media:
Colleen Hussey

Senior Manager, Corporate Communications

203-470-5620

[email protected]

Dan Budwick

1AB

973-271-6085

[email protected]

Investors:
Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]

Research includes innovations in mRNA and protein engineering and delivery science to improve therapeutic properties

Highlights research results from ongoing collaborations with International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID) and Bill & Melinda Gates Foundation toward development of an HIV vaccine

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new research to be highlighted at the Company’s third annual Science Day, held virtually this year. The program is designed to provide insight into the continued diverse efforts underway at Moderna and with collaborators to better understand how to use mRNA as a medicine, and underscores the Company’s continued commitment to basic science and innovation.

“Science Day is an opportunity for us to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as a medicine. Our substantial investments in basic science to date have resulted in major steps forward in our platform’s capabilities, and these have allowed us to open new therapeutic areas and new scientific directions,” said Stephen Hoge, M.D., President of Moderna. “Today, we’re excited to highlight novel approaches to our lipid nanoparticle technology, which will be used with mRNA-3745, our GSD1a candidate in preclinical development. We are also pleased to provide an update on our collaboration with IAVI, NIAID and Bill & Melinda Gates Foundation toward the development of an HIV vaccine using Moderna’s mRNA platform. We remain firmly committed to further advancing our mRNA science to create a new generation of transformative medicines for patients.”

At this year’s Science Day, Moderna will present new platform science and preclinical research, including:

Engineering mRNA and Proteins to Improve Therapeutic Properties

An advantage of mRNA medicines over small molecule drugs is the ease of engineering their properties to achieve desired pharmacology. New research will be presented on efforts to engineer both mRNAs and encoded proteins to improve and extend therapeutic effect.

These efforts include modifications to mRNA and proteins to prevent degradation and lengthen half-life. Presentations will include data on the addition of an inverted deoxythymidine (idT) to the 3’-end of mRNA, which is designed to stabilize mRNA by blocking its degradation through deadenylation. Preclinical data show that 3’-idT-stabilized mRNA encoding phenylalanine hydroxylase (PAH), the enzyme missing or dysfunctional in the metabolic disorder phenylketonuria (PKU), supports sustained reduction of serum phenylalanine levels in a PKU mouse model. Data will also be presented on removal of ubiquitination sites from PAH, designed to prevent ubiquitin-mediated protein degradation. Results show that combining mRNA stabilization along with PAH stabilization maintained low serum phenylalanine levels even further, suggesting an additive effect.

One challenge for the production of mRNA therapeutics is to minimize or eliminate double-stranded RNA (dsRNA) impurities produced during the synthesis process, as this can trigger undesirable innate immune responses in vivo. At Science Day, Moderna will present a protein engineering workflow by which it has engineered a Moderna T7 RNA polymerase (MT7) that does not produce dsRNA impurities.

Optimizing Lipid Nanoparticle Technology

The Company will present new research in delivery science to optimize its lipid nanoparticles (LNPs). The presentations will highlight a novel squaramide-based ionizable lipid designed to enhance the interactions between the lipid and mRNA. Preclinical data from new LNPs incorporating this novel ionizable lipid show improved protein expression after IV administration, including repeat dosing, and efficient delivery to the liver, as compared to current state-of-the-art Moderna proprietary LNPs.

This squaramide-based LNP represents a new delivery system and will be used with the Company’s glycogen storage disease type 1a (GSD1a) candidate (mRNA-3745), which is in preclinical development. Preclinical studies with this new LNP containing mRNA encoding for G6Pase, the missing or dysfunctional enzyme in GSD1a, show sustained improvements in fasting blood glucose in a mouse model of GSD1a, achieving the target product profile.

Collaborating on an HIV Vaccine

Science Day will also include presentations from William Schief, Ph.D., Professor, Immunology and Microbiology, Scripps Research Institute and Executive Director, Vaccine Design, International Aids Vaccine Initiative (IAVI) and Paolo Lusso, M.D., Ph.D., Chief, Viral Pathogenesis, Laboratory of Immmunoregulation, National Institute of Allergy and Infectious Diseases (NIAID)​ showcasing research conducted through Moderna’s ongoing collaborations with IAVI, NIAID and the Bill & Melinda Gates Foundation. This research seeks to deliver an engineered HIV immunogen using Moderna’s mRNA platform that allows for a faster, more flexible approach to rapid iterative vaccine design and clinical testing. This approach could significantly accelerate early clinical trials and transform HIV vaccine science and development efforts. The data presented today will highlight progress toward creating a protective HIV-1 vaccine designed to elicit broadly neutralizing antibodies to prevent HIV-1 infection.

Moderna currently has 23 mRNA development candidates in its portfolio with 13 in clinical studies. Across Moderna’s pipeline, more than 1,900 participants have been enrolled in clinical studies. The Company’s updated pipeline can be found at www.modernatx.com/pipeline. Moderna and collaborators have published more than 45 peer-reviewed papers.

Science Day Webcast Information

Moderna will host its annual Science Day for analysts and investors at 8:00 a.m. ET on Tuesday, June 2. A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for one year following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s mRNA and encoded protein engineering efforts, the Company’s new squaramide-based LNP and its expected use with mRNA-3745 and other new development candidates, the potential for the Company’s mRNA platform to significantly accelerate early clinical trials and transform HIV vaccine science and development efforts, and the presentation of research and data at the Company’s upcoming Science Day. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. 

Contacts

Moderna Contacts

Media:
Colleen Hussey

Senior Manager, Corporate Communications

203-470-5620

[email protected]

Dan Budwick

1AB

973-271-6085

[email protected]

Investors:
Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]